Lantern Pharma announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to LP-284 for the treatment of soft tissue sarcomas, marking the third orphan designation for the program and the sixth overall across the company's clinical pipeline. The designation expands LP-284 beyond hematologic malignancies into solid tumors and reflects its synthetic lethal mechanism targeting DNA repair deficiencies, which are common in adult soft tissue sarcomas. Lantern said the designation supports an accelerated regulatory pathway for LP-284 as it continues Phase 1 evaluation in B-cell non-Hodgkin lymphomas and advances development in additional rare cancer indications.
The company's proprietary RADR AI platform integrates hundreds of billions of data points to identify biomarkers, predict drug response, and design smarter clinical trials. Lantern's clinical-stage pipeline includes LP-184, LP-284, and LP-300, each targeting genomically defined patient populations. The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. BioMedWire is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
